Modello di stima dei costi sanitari e della capacity delle terapie intensive in Italia nel trattamento di pazienti affetti da COVID-19: valutazione dell’impatto di remdesivir
Introduction: Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome coronavirus 2, which is a human coronavirus responsible for a pandemic. Direct interventions, i.e. physical distancing and use of protective devices, can prevent or limit contagions, however, it is also required to evaluate the optimization of limited resources, such as the Intensive Care Unit (ICU). For this purpose, it is relevant to estimate the impact of therapeutic solutions that reduce the probability that the patient transits to ICU in symptomatic subjects and in need of hospitalization. The therapeutic solutions allow a more rapid recovery of the patient and save scarce resources that can be used in the treatment of other patients.
Methods: A forecasting model is designed to estimate the impact of one therapeutic solution, i.e. the antiretroviral Remdesivir, on both the capacity of intensive care and the healthcare costs for hospitals when managing the current emergency. A base case is presented as well as a best and a worst case scenario deriving from the sensitivity analyses.
Results: The introduction of Remdesivir in patients receiving low-flow oxygen therapy with the purpose of reducing ICU accesses and deaths leads to 431 million euros cost savings and avoids 17,150 hospitalizations in intensive care and 6,923 deaths. In the best case, 294 million euros savings are estimated, whilst in the worst case the model estimates a saving of 512 million euros.
Conclusions: Remdesivir has the potential to reduce the negative effects of the Coronavirus disease, improving patient conditions and reducing death tolls, and can also save scarce healthcare resources during this pandemic, resulting in a shorter hospital stay and fewer ICU admissions.
Istituto Superiore di Sanità, Epidemia COVID-19, aggiornamento nazionale, 25 novembre 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_25-novembre-2020.pdf
Istituto Nazionale di Statistica, Conti Economici Trimestrali, 2 ottobre 2020. (Accessed November 2020). https://www.istat.it/it/archivio/247904
Healthcare Datascience Lab, Centro sull’Economia e sul Management nella Sanità e nel Sociale, assorbimento di risorse economiche correlato alla gestione ospedaliera dei pazienti COVID-19 (Accessed November 2020). https://www.quotidianosanita.it/studi-e-analisi/articolo.php?articolo_id=86648
ALTEMS, Alta Scuola di Economia e Management dei Sistemi Sanitari, COVID-19, Instant REPORT#18: 03 settembre 2020. https://altems.unicatt.it/altems-instant%20report%2018.pdf
Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS), Rapporto COVID-19 (Accessed November 2020). https://www.agenas.gov.it/covid19/web/index.php?r=site%2Ftab2
Summary of product characteristics (SMPC), Remdesivir. (Accessed November 2020). https://www.ema.europa.eu/en/documents/other/veklury-product-information-approved-chmp-25-june-2020-pending-endorsement-european-commission_en.pdf
Agenzia Italiana del Farmaco (AIFA). Emergenza COVID-19, Procedura di richiesta per il farmaco Veklury® (remdesivir). (Accessed November, 2020). https://www.aifa.gov.it/-/procedura-di-richiesta-per-il-farmaco-veklury-remdesivir-
Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the Treatment of COVID-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. https://doi.org/10.1056/NEJMoa2007764 PMID:32445440
Bassi F, Arbia G, Falorsi PD. Observed and estimated prevalence of COVID-19 in Italy: how to estimate the total cases from medical swabs data. Sci Total Environ. 2020;142799:142799; Epub ahead of print. https://doi.org/10.1016/j.scitotenv.2020.142799 PMID:33066965
ISTAT. Indagine di sieroprevalenza sul SARS-CoV-2. (Accessed November 2020). https://www.istat.it/it/files/2020/08/ReportPrimiRisultatiIndagineSiero.pdf
Grasselli G, Zangrillo A, Zanella A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2
admitted for ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. https://doi.org/10.1001/jama.2020.5394 PMID: 32250385
Ministero dell’Economia e delle Finanze – Commissione Tecnica per la Finanza Pubblica. Libro verde sulla spesa pubblica (2007). http://www.mef.gov.it/ministero/commissioni/ctfp/documenti/Libro_verde_spesa_pubblica.pdf
ALTEMS, Alta Scuola di Economia e Management dei Sistemi Sanitari, COVID-19, Instant REPORT#28: 12 novembre 2020. https://altems.unicatt.it/altems-Altems%20Instant%20Report%20n28.pdf
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225-1228. https://doi.org/10.1016/S0140-6736(20)30627-9 PMID:32178769
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2020;395(10236):1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9 PMID:32423584
Spinner CD, Gottlieb RL, Criner GJ, et al; GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048-1057. https://doi.org/10.1001/jama.2020.16349 PMID:32821939
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. N Engl J Med. 2020;383:1827-1837. https://doi.org/10.1056/NEJMoa2015301. PMCID: PMC7377062
World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. (Accessed November 2020). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Copyright (c) 2020 The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.